Calendario›SKYE›SBI-100 Ophthalmic Emulsion

SBI-100 Ophthalmic Emulsion

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

Ensayo de Skye Bioscience, Inc. en Primary Open Angle Glaucoma · Ocular Hypertension (del registro, en inglés).

Más ensayos de: Hipertensión ocular.

Fase

Fase 2

Estado

Completado

Participantes

56

previstos

Centros

3

Fin del objetivo primario

feb 2024

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en nov 2023.

Qué mide

Change From Baseline in Ocular Hypertension as Measured by Intraocular Pressure (IOP) (del registro, en inglés) (inicio y dia 14)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients with elevated pressure in the eye. Patients will be randomly given either: * 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion * 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion * Placebo Ophthalmic Emulsion Patients will be tested before starting and will have one drop of the product placed into each eye twice a day for 14 days, by the site and by the patient. At the end of the study, researchers will compare the groups to see if there is a change from before use of SBI-100 Ophthalmic Emulsion to the end of study.

Más ensayos de SKYE

Todos los de SKYE, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06144918), actualizada en ene 2026.